A large retrospective cohort pharmacoepidemiologic study found that despite approval by the U.S. Food and Drug Administration (FDA) for 7 new gram-negative antibiotics between 2014 and 2019, clinicians in U.S. hospitals still treated more than 40 percent of patients battling highly resistant pathogens exclusively with older, generic agents.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
